Patent ID: RE45198

Claim:
A method for treating gastric acid disorders selected from the group consisting of active duodenal ulcers, gastric ulcers, gastroesophageal reflux disease (GERD), severe erosive esophagitis, poorly responsive systematic GERD, and Zollinger Ellison Syndrome by administering to a patient in a single dose of a pharmaceutical composition of omeprazole or lansoprazole powder in a pharmaceutically acceptable carrier consisting essentially of a bicarbonate salt of a Group IA metal wherein said administering step consists of providing to the patient orally in a single dose of of an aqueous solution or , suspension of the pharmaceutical composition without requiring further administration of the bicarbonate salt of the Group IA metal , wherein upon oral administration of the suspension at least some of the omeprazole or lansoprazole is absorbed within about 10 to about 12 minutes after administration .